Cognition, mood & sleep

A set of neuropeptides is studied for effects on cognition, mood, anxiety, neuroprotection, and sleep. A recurring theme in this area is that the evidence is often regional (much of it from Russian research) or older and inconsistent, and rarely replicated in large international trials.

Semax and Selank are Russian-developed peptides: Semax studied mainly for nootropic/neuroprotective effects (often linked to BDNF), Selank mainly as an anxiolytic. Both are registered as medicines in Russia but not approved by the FDA or EMA, and their evidence base lacks broad independent replication. Cerebrolysin is not a single peptide but a porcine-brain peptide mixture, marketed in many countries for stroke and dementia, though independent Cochrane reviews have not confirmed benefit for stroke. DSIP (delta sleep-inducing peptide) is the weakest-supported of the group: despite its name, its sleep effects are inconsistent and it has no established receptor or mechanism.

Conditions people ask about

Popular videos and high-claim content in this area promise to "reverse," "cure," or dramatically slow conditions like Alzheimer's, Parkinson's, anxiety, and depression with neurotrophic or "mitochondrial" peptides. That framing is not supported by the evidence: no compound on this site is an approved treatment for any condition below, and reversal claims lack controlled human evidence. The notes here are meant to answer common searches honestly, not to serve as a treatment guide. Every condition below is a matter for a licensed clinician and a proper diagnostic workup — a research peptide is not a substitute for diagnosis or care.

Dementia and Alzheimer's disease

High-claim content frames Alzheimer's and other dementias as "reversible," or at least dramatically slowable, with a neurotrophic-peptide protocol that supposedly regrows brain tissue and restores memory. In reality, no compound on this wiki is an FDA- or EMA-approved treatment for Alzheimer's or any dementia, and there is no controlled human evidence that any of them reverses cognitive decline; the most-studied one is approved as a neurotrophic agent in some countries but not by the FDA or EMA, and independent Cochrane reviews found no clear benefit for vascular dementia and only very-low-certainty signals in Alzheimer's [Human]. Dementia is a serious diagnosis requiring a licensed clinician and proper workup — a research peptide is not a substitute for diagnosis or care. Compounds discussed in this context: Cerebrolysin, a porcine-brain-derived peptide/amino-acid mixture approved as a neurotrophic agent in several countries but not by the FDA or EMA — the most-studied compound here for dementia, yet Cochrane reviews report no clear benefit for vascular dementia and only very-low-certainty, disputed signals in Alzheimer's, with a probable increase in non-fatal serious adverse events (studied, not established as effective) [Human]; Humanin, a mitochondrial-derived peptide first identified in Alzheimer's research for rescuing neurons from cell death in the lab, whose Alzheimer's link is entirely cell- and animal-level with no completed human therapeutic trials (preclinical research interest only) [In vitro/Animal]; Pinealon, a synthetic Glu-Asp-Arg tripeptide from the Khavinson "bioregulator" school marketed with neuroprotective/nootropic framing, with cognitive and Alzheimer's-model data in vitro and in rodents and older, single-group, unreplicated Russian human reports (a research reagent, not approved anywhere) [Animal/In vitro]; and Cortagen, a synthetic Ala-Glu-Asp-Pro tetrapeptide from the same Khavinson lineage promoted as a brain "bioregulator," with thin, older, almost entirely preclinical evidence and no published human clinical trial (research reagent only) [Animal/In vitro].

Parkinson's disease

Popular videos suggest Parkinson's motor decline can be halted or reversed with "mitochondrial" and neurotrophic peptides that supposedly protect or regenerate dopamine neurons. No compound on this wiki is an approved treatment for Parkinson's disease, and there is no controlled human evidence that any of them slows, halts, or reverses it — community discussion leans on general neuroprotection and mitochondrial rationales rather than Parkinson's-specific human trials, and several mitochondrial candidates have actually missed their primary endpoints [Human]. Parkinson's is a serious neurological diagnosis that requires a licensed clinician — a research peptide is not a substitute for specialist care. Compounds discussed in this context: Cerebrolysin, marketed as a neurotrophic agent and studied in various neurological settings but with disputed evidence and no FDA/EMA approval, and no robust controlled human evidence that it changes the course of Parkinson's specifically (discussed, not established) [Human]; SS-31, a mitochondria-targeting tetrapeptide (elamipretide) that stabilizes cristae by binding cardiolipin, with an extensive but mixed human trial record and its only approval (2025 FDA accelerated approval) for the ultra-rare Barth syndrome, not Parkinson's — any Parkinson's use is investigational/preclinical rationale only [Human/Animal]; and Methylene Blue, a small-molecule redox dye (not a peptide) approved only for methemoglobinemia, whose "mitochondrial" neuroprotective appeal is largely in vitro and animal with no controlled human evidence in Parkinson's, and which is a potent MAOI with real serotonin-syndrome risk (off-label and unproven for this) [In vitro/Animal].

Anxiety and "brain fog"

The community markets certain nootropic/anxiolytic peptides as a clean, non-pharmaceutical way to erase anxiety and clear "brain fog" within days, framed as an upgrade over prescription anti-anxiety medication. No compound on this wiki is FDA- or EMA-approved for an anxiety disorder, and "brain fog" is not a medical diagnosis but a symptom of many underlying conditions; the peptides discussed here rest largely on small, mostly Russian studies or on mechanism/animal work rather than large replicated Western trials, so their anxiolytic effect in humans is best described as investigational or unproven [Human/Animal]. Persistent anxiety or cognitive complaints should be assessed by a licensed clinician to find the real cause — a research peptide is not a substitute for diagnosis or evidence-based treatment. Compounds discussed in this context: Selank, a synthetic tuftsin-analog heptapeptide registered as an anxiolytic in Russia but not FDA/EMA approved, whose anti-anxiety evidence rests largely on small Russian studies and GABAergic/monoaminergic mechanism work without large replicated Western trials (studied, not established) [Human/Animal]; Semax, a Russian-registered ACTH(4-10) analog used as a nootropic/neuroprotective nasal medicine and not FDA/EMA approved, with cognition and attention claims relevant to "brain fog" coming mostly from unreplicated Russian research linked to BDNF signaling (discussed, not established outside Russia) [Human/Animal]; BPC-157, a synthetic gastric-derived peptide with anxiolytic-like and neuroprotective effects reported only in animal "gut-brain axis" models, with no controlled human evidence for anxiety or brain fog and no approval anywhere (preclinical rationale only) [Animal]; and DSIP, delta sleep-inducing peptide sometimes cited for stress and the HPA axis, whose effects are inconsistent, which has no identified receptor, and whose human data are sparse and dated with no controlled human evidence for anxiety (a research chemical, not a treatment) [Human/Animal].

Depression

High-claim content presents certain peptides as fast-acting, side-effect-free antidepressants that raise BDNF and "reset" mood without the downsides of SSRIs. No compound on this wiki is FDA- or EMA-approved for major depression, and there is no controlled human evidence that any of them treats a depressive disorder — antidepressant-like claims trace to animal models and BDNF-signaling mechanisms, or to small non-replicated studies, not to large randomized human antidepressant trials [Human/Animal]. Depression is a serious, sometimes life-threatening condition that requires a licensed clinician; if you are struggling, seek professional help — a research peptide is not a substitute for diagnosis or treatment. Compounds discussed in this context: Semax, a Russian-registered ACTH(4-10) analog studied for neuroprotection and cognition and often discussed around BDNF, whose mood/antidepressant framing rests on mechanism and small Russian research rather than replicated human antidepressant trials, and which is not FDA/EMA approved [Human/Animal]; Selank, a tuftsin-analog anxiolytic peptide registered in Russia and discussed for mood via monoaminergic and enkephalin-related mechanisms, but with small-study and animal-level evidence and no approved antidepressant indication (investigational at best) [Human/Animal]; BPC-157, reported to have antidepressant-like effects only in rodent forced-swim-type and gut-brain-axis models, with no controlled human evidence for depression and no approval anywhere (preclinical signal only) [Animal]; and Oxytocin, an approved obstetric hormone (Pitocin/Syntocinon) whose famous mood, bonding, and social-anxiety claims come from a separate body of mostly intranasal research that is mixed and frequently fails to replicate — it is NOT an approved treatment for depression, and depression-specific human evidence is inconsistent (investigational for mood) [Human].